Close Menu

HIV

A flurry of recently published peer-reviewed papers has demonstrated the growing breadth and diversity of applications for Bio-Rad's QX100 Droplet Digital PCR system.

Bay Area molecular diagnostics shop Wave 80 Biosciences is gearing up to evaluate its first product — a semi-quantitative HIV viral load assay that runs on the company's cartridge-based, near-patient, sample-to-answer testing system — in full-scale clinical trials by the end of t

After buying small microRNA firm Prestizia last June, France's Theradiag is moving forward in development of several miRNA tests in the HIV disease area, as well as two companion diagnostic projects for experimental therapies, one for HIV and another for obesity under a $1.6 mill

The National Institutes of Health recently announced two funding opportunities for research initiatives with potential microRNA and non-coding RNA aspects including one related to the treatment of HIV-1 and another to lung development research.

UK-based molecular diagnostics developer Lumora has partnered with the Foundation for Innovative New Diagnostics to develop a rapid, high-throughput malaria diagnostic assay to screen patients in the developing world.

Scientists from Seattle's PATH institute, the Fred Hutchinson Cancer Research Center, and Alere subsidiary TwistDx have published a paper demonstrating the rapid detection of HIV-1 proviral DNA using assays based on TwistDx's recombinase polymerase amplification, an isothermal am

NEW YORK (GenomeWeb News) – Alere said today that it has been awarded a grant of up to $21.6 million and debt financing of up to $20.6 million from the Bill and Melinda Gates Foundation to further develop a pair of point-of-care molecular testing platforms.

Health management services and diagnostics firm Alere recently updated investors on the progress of a pair of nucleic acid testing platforms that are currently under development at the company and represent the firm's entrée into molecular diagnostics.

Quidel disclosed this week that it has been awarded a milestone-based grant from the Bill and Melinda Gates Foundation to support the development, validation, and manufacture of a low-cost quantitative nucleic acid test to monitor HIV drug treatment.

Researchers testing a prototype of a Roche next-gen sequencing assay to measure drug resistance in HIV patients recently reported that the test's performance was comparable to Siemen's TruGene assay, which uses real-time PCR and Sanger sequencing and is approved by the US Food an

Pages

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.